Skip to main navigation Skip to search Skip to main content

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

  • Michael Wang
  • , Javier Munoz
  • , Andre Goy
  • , Frederick L. Locke
  • , Caron A. Jacobson
  • , Brian T. Hill
  • , John M. Timmerman
  • , Houston Holmes
  • , Samantha Jaglowski
  • , Ian W. Flinn
  • , Peter A. Mcsweeney
  • , David B. Miklos
  • , John M. Pagel
  • , Marie José Kersten
  • , Krimo Bouabdallah
  • , Rashmi Khanal
  • , Max S. Topp
  • , Roch Houot
  • , Amer Beitinjaneh
  • , Weimin Peng
  • Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan
  • University of Texas MD Anderson Cancer Center
  • Banner Health
  • Moffitt Cancer Center
  • Dana-Farber Cancer Institute
  • Cleveland Clinic Foundation
  • University of California at Los Angeles
  • Texas Oncology
  • Ohio State University
  • Sarah Cannon Research Institute
  • Colorado Blood Cancer Institute
  • Stanford University
  • Swedish Medical Center
  • University of Amsterdam
  • Centre Hospitalier Universitaire de Bordeaux
  • Fox Chase Cancer Center
  • University of Würzburg
  • Université de Rennes
  • University of Miami
  • Kite, a Gilead Company
  • University of Rochester

Research output: Contribution to journal › Article › peer-review

314 Scopus citations

Abstract

PURPOSEBrexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics.METHODSPatients with relapsed/refractory MCL (one to five prior therapies, including prior BTKi exposure) received a single infusion of KTE-X19 (2 × 106 CAR T cells/kg).RESULTSAfter a median follow-up of 35.6 months, the objective response rate among all 68 treated patients was 91% (95% CI, 81.8 to 96.7) with 68% complete responses (95% CI, 55.2 to 78.5); medians for duration of response, progression-free survival, and overall survival were 28.2 months (95% CI, 13.5 to 47.1), 25.8 months (95% CI, 9.6 to 47.6), and 46.6 months (95% CI, 24.9 to not estimable), respectively. Post hoc analyses showed that objective response rates and ongoing response rates were consistent among prespecified subgroups by prior BTKi exposure or high-risk characteristics. In an exploratory analysis, patients with prior bendamustine benefited from KTE-X19, but showed a trend toward attenuated T-cell functionality, with more impact of bendamustine given within 6 versus 12 months of leukapheresis. Late-onset toxicities were infrequent; only 3% of treatment-emergent adverse events of interest in ZUMA-2 occurred during this longer follow-up period. Translational assessments revealed associations with long-term benefits of KTE-X19 including high-peak CAR T-cell expansion in responders and the predictive value of minimal residual disease for relapse.CONCLUSIONThese data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.

Original languageEnglish
Article number02370
JournalJournal of Clinical Oncology
Volume94
DOIs
StatePublished - 1 May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study'. Together they form a unique fingerprint.

Cite this